GSK Vaccine Boostrix Gets Boost from FDA Older Adults Approval

The FDA is expanding the use of GlaxoSmithKline’s (GSK) diphtheria, pertussis (whooping cough) and tetanus vaccine Boostrix to include patients age 65 and older, making it the first single-dose vaccine approved to prevent all three diseases in this population.
Washington Drug Letter